CoLucid Pharmaceuticals, Inc. 4

4 · CoLucid Pharmaceuticals, Inc. · Filed Mar 1, 2017

Form 4

Period: 2017-03-01

Director

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2017-03-01$38.00/sh−997$37,886→ 0 total
Exercise: $8.50Exp: 2026-01-04→ Common Stock (997 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2017-03-01$40.26/sh−8,897$358,193→ 0 total
Exercise: $6.24Exp: 2026-05-10→ Common Stock (8,897 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2017-03-01$36.88/sh−1,630$60,114→ 0 total
Exercise: $9.62Exp: 2026-07-01→ Common Stock (1,630 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2017-03-01$37.90/sh−6,577$249,268→ 0 total
Exercise: $8.60Exp: 2025-07-09→ Common Stock (6,577 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2017-03-01$10.30/sh−453$4,666→ 0 total
Exercise: $36.20Exp: 2027-01-03→ Common Stock (453 underlying)

Footnotes (2)

[F1]Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
[F2]Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.

Documents

1 file